$ cat ./records/gates-foundation-commits-82-9-million-to-aeras-for-tuberculosis-v-2004.txt
Gates Foundation Commits $82.9 Million to Aeras for Tuberculosis Vaccines
[RECORD.TXT] · cat --full
The Gates Foundation awarded $82.9 million to the Aeras Global TB Vaccine Foundation, described at the time as the largest-ever single grant for tuberculosis vaccine research. The funding more than doubled global annual TB vaccine R&D spending and enabled Aeras to run clinical trials of multiple vaccine candidates in South Africa, Uganda, and other high-burden countries. The grant established TB vaccine development as a serious biomedical priority after decades of neglect.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Co-Funds Pediatric Dengue Vaccine Initiative with PATH to Advance Dengvaxia
Next →
Awarded $35 million to Zambia's national malaria control program to scale up bed net distribution
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.